S7 Estimating the potential impact of residual EDS on the QoL of patients with OSA and, for the first time, their partners, using a time trade-off methodology
Introduction and ObjectivesExcessive daytime sleepiness (EDS) is a common symptom of obstructive sleep apnoea (OSA), persisting in 9% to 22% of patients despite primary airway therapy (residual EDS). EDS can impair work productivity and driving ability, and negatively impact quality of life (QoL) of...
Gespeichert in:
Veröffentlicht in: | Thorax 2021-11, Vol.76 (Suppl 2), p.A8-A9 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | A9 |
---|---|
container_issue | Suppl 2 |
container_start_page | A8 |
container_title | Thorax |
container_volume | 76 |
creator | Tolley, K Mettam, S Noble-Longster, J Hibbs, R Stainer, L Cawson, M Snell, T Manuel, A |
description | Introduction and ObjectivesExcessive daytime sleepiness (EDS) is a common symptom of obstructive sleep apnoea (OSA), persisting in 9% to 22% of patients despite primary airway therapy (residual EDS). EDS can impair work productivity and driving ability, and negatively impact quality of life (QoL) of patients and their partners.This study aimed to elicit QoL values (utilities) from a societal perspective for patients with OSA with residual EDS of varying severity and, for the first time, for the partners of these patients, using a novel time trade-off (TTO) approach.MethodsUtility values for health states of varying severities of residual EDS in OSA were elicited using the TTO method in a study conducted with a United Kingdom general public sample (N=110). Four EDS severity health state descriptions were developed from both patient and partner perspectives (no EDS, mild EDS, moderate EDS, severe EDS). During face-to-face interviews, participants were asked to ‘trade off’ time for each EDS health state for a shorter period in full health (0–10 years), first for the patient health states and then for the partner health states. TTO responses were converted to utility values (scale of 0–1, where 0 represents QoL equivalent to death and 1 represents the highest QoL).ResultsMean utility scores declined with increasing EDS severity (table 1). In the context of the TTO exercise, participants were prepared to trade a mean of 4.5 life-years (out of a maximum of 10) to avoid the QoL consequences of severe EDS compared with best imaginable health and 3.3 life-years to avoid the QoL impact associated with being the partner of a patient with severe EDS.Abstract S7 Table 1Utility values for patient and partner health states (N=104)a Utility Valuesb Mean SD Patient health states 1. No EDS 0.93 0.11 2. Mild EDS 0.79 0.17 3. Moderate EDS 0.61 0.22 4. Severe EDS 0.55 0.24 Partner health states 5. No EDS 0.95 0.08 6. Mild EDS 0.88 0.13 7. Moderate EDS 0.75 0.23 8. Severe EDS 0.67 0.26 EDS, excessive daytime sleepiness; SD, standard deviation. aAll values rounded to 2 decimal places. bBased on a scale of 0–1, where 0 represents QoL equivalent to death and 1 represents the highest QoL.ConclusionsThese results demonstrate the high potential impact of residual EDS on the QoL of patients with OSA and their partners. Estimated utility values for patients and partners declined with increased EDS severity. This is the first time that the impact of residual EDS in OSA on QoL and utilit |
doi_str_mv | 10.1136/thorax-2021-BTSabstracts.13 |
format | Article |
fullrecord | <record><control><sourceid>proquest_bmj_j</sourceid><recordid>TN_cdi_proquest_journals_2594959048</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2594959048</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1293-57b290efb39f047261adae38796563a660e134de2c715480484400c11e1429003</originalsourceid><addsrcrecordid>eNpNkU1OwzAQhS0EEqVwB0vdNsUTO06yLKX8SJUqlLKOnMZuUzVxsB0BOzbcg7NxEpwWCVbWeL43b0YPoRGQCQDl126rjXgLQhJCcLPKRGGdEWtnJ0BP0AAYTwIapvwUDQhhJOA05ufowtodISQBiAfoK4u_Pz7n1lW1cFWzwW4rcaudbFwl9riqWz8Pa4WNtFXZ-a_5bYZ1c-Ce9KJvtV7peYtfK7fFy2yKRVOOsdLmQKnKWIe9gRz3dWW8wLhGGjvGne09xaGL_e6lDLRSuJb-slLv9eb9Ep0psbfy6vcdoue7-Wr2ECyW94-z6SIoIExpEMVFmBKpCpoqwuKQgyiFpEmc8ohTwTmRQFkpw3UMEUsISxgjZA0ggXkhoUM0Os5tjX7ppHX5Tnem8ZZ5GKUsjVKv8VR8pIp69wcAyfs48mMceR9H_j-OHCj9AZblhIU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2594959048</pqid></control><display><type>article</type><title>S7 Estimating the potential impact of residual EDS on the QoL of patients with OSA and, for the first time, their partners, using a time trade-off methodology</title><source>Alma/SFX Local Collection</source><creator>Tolley, K ; Mettam, S ; Noble-Longster, J ; Hibbs, R ; Stainer, L ; Cawson, M ; Snell, T ; Manuel, A</creator><creatorcontrib>Tolley, K ; Mettam, S ; Noble-Longster, J ; Hibbs, R ; Stainer, L ; Cawson, M ; Snell, T ; Manuel, A</creatorcontrib><description>Introduction and ObjectivesExcessive daytime sleepiness (EDS) is a common symptom of obstructive sleep apnoea (OSA), persisting in 9% to 22% of patients despite primary airway therapy (residual EDS). EDS can impair work productivity and driving ability, and negatively impact quality of life (QoL) of patients and their partners.This study aimed to elicit QoL values (utilities) from a societal perspective for patients with OSA with residual EDS of varying severity and, for the first time, for the partners of these patients, using a novel time trade-off (TTO) approach.MethodsUtility values for health states of varying severities of residual EDS in OSA were elicited using the TTO method in a study conducted with a United Kingdom general public sample (N=110). Four EDS severity health state descriptions were developed from both patient and partner perspectives (no EDS, mild EDS, moderate EDS, severe EDS). During face-to-face interviews, participants were asked to ‘trade off’ time for each EDS health state for a shorter period in full health (0–10 years), first for the patient health states and then for the partner health states. TTO responses were converted to utility values (scale of 0–1, where 0 represents QoL equivalent to death and 1 represents the highest QoL).ResultsMean utility scores declined with increasing EDS severity (table 1). In the context of the TTO exercise, participants were prepared to trade a mean of 4.5 life-years (out of a maximum of 10) to avoid the QoL consequences of severe EDS compared with best imaginable health and 3.3 life-years to avoid the QoL impact associated with being the partner of a patient with severe EDS.Abstract S7 Table 1Utility values for patient and partner health states (N=104)a Utility Valuesb Mean SD Patient health states 1. No EDS 0.93 0.11 2. Mild EDS 0.79 0.17 3. Moderate EDS 0.61 0.22 4. Severe EDS 0.55 0.24 Partner health states 5. No EDS 0.95 0.08 6. Mild EDS 0.88 0.13 7. Moderate EDS 0.75 0.23 8. Severe EDS 0.67 0.26 EDS, excessive daytime sleepiness; SD, standard deviation. aAll values rounded to 2 decimal places. bBased on a scale of 0–1, where 0 represents QoL equivalent to death and 1 represents the highest QoL.ConclusionsThese results demonstrate the high potential impact of residual EDS on the QoL of patients with OSA and their partners. Estimated utility values for patients and partners declined with increased EDS severity. This is the first time that the impact of residual EDS in OSA on QoL and utility has been measured from the partner perspective, highlighting the range of potential benefits that could result from the use of novel treatment options (alongside primary airway therapy) for residual EDS.Please refer to page A188 for declarations of interest related to this abstract.</description><identifier>ISSN: 0040-6376</identifier><identifier>EISSN: 1468-3296</identifier><identifier>DOI: 10.1136/thorax-2021-BTSabstracts.13</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and British Thoracic Society</publisher><subject>Patients ; Sleep apnea ; Stay awake! It’s an update on sleep</subject><ispartof>Thorax, 2021-11, Vol.76 (Suppl 2), p.A8-A9</ispartof><rights>Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27926,27927</link.rule.ids></links><search><creatorcontrib>Tolley, K</creatorcontrib><creatorcontrib>Mettam, S</creatorcontrib><creatorcontrib>Noble-Longster, J</creatorcontrib><creatorcontrib>Hibbs, R</creatorcontrib><creatorcontrib>Stainer, L</creatorcontrib><creatorcontrib>Cawson, M</creatorcontrib><creatorcontrib>Snell, T</creatorcontrib><creatorcontrib>Manuel, A</creatorcontrib><title>S7 Estimating the potential impact of residual EDS on the QoL of patients with OSA and, for the first time, their partners, using a time trade-off methodology</title><title>Thorax</title><addtitle>Thorax</addtitle><description>Introduction and ObjectivesExcessive daytime sleepiness (EDS) is a common symptom of obstructive sleep apnoea (OSA), persisting in 9% to 22% of patients despite primary airway therapy (residual EDS). EDS can impair work productivity and driving ability, and negatively impact quality of life (QoL) of patients and their partners.This study aimed to elicit QoL values (utilities) from a societal perspective for patients with OSA with residual EDS of varying severity and, for the first time, for the partners of these patients, using a novel time trade-off (TTO) approach.MethodsUtility values for health states of varying severities of residual EDS in OSA were elicited using the TTO method in a study conducted with a United Kingdom general public sample (N=110). Four EDS severity health state descriptions were developed from both patient and partner perspectives (no EDS, mild EDS, moderate EDS, severe EDS). During face-to-face interviews, participants were asked to ‘trade off’ time for each EDS health state for a shorter period in full health (0–10 years), first for the patient health states and then for the partner health states. TTO responses were converted to utility values (scale of 0–1, where 0 represents QoL equivalent to death and 1 represents the highest QoL).ResultsMean utility scores declined with increasing EDS severity (table 1). In the context of the TTO exercise, participants were prepared to trade a mean of 4.5 life-years (out of a maximum of 10) to avoid the QoL consequences of severe EDS compared with best imaginable health and 3.3 life-years to avoid the QoL impact associated with being the partner of a patient with severe EDS.Abstract S7 Table 1Utility values for patient and partner health states (N=104)a Utility Valuesb Mean SD Patient health states 1. No EDS 0.93 0.11 2. Mild EDS 0.79 0.17 3. Moderate EDS 0.61 0.22 4. Severe EDS 0.55 0.24 Partner health states 5. No EDS 0.95 0.08 6. Mild EDS 0.88 0.13 7. Moderate EDS 0.75 0.23 8. Severe EDS 0.67 0.26 EDS, excessive daytime sleepiness; SD, standard deviation. aAll values rounded to 2 decimal places. bBased on a scale of 0–1, where 0 represents QoL equivalent to death and 1 represents the highest QoL.ConclusionsThese results demonstrate the high potential impact of residual EDS on the QoL of patients with OSA and their partners. Estimated utility values for patients and partners declined with increased EDS severity. This is the first time that the impact of residual EDS in OSA on QoL and utility has been measured from the partner perspective, highlighting the range of potential benefits that could result from the use of novel treatment options (alongside primary airway therapy) for residual EDS.Please refer to page A188 for declarations of interest related to this abstract.</description><subject>Patients</subject><subject>Sleep apnea</subject><subject>Stay awake! It’s an update on sleep</subject><issn>0040-6376</issn><issn>1468-3296</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpNkU1OwzAQhS0EEqVwB0vdNsUTO06yLKX8SJUqlLKOnMZuUzVxsB0BOzbcg7NxEpwWCVbWeL43b0YPoRGQCQDl126rjXgLQhJCcLPKRGGdEWtnJ0BP0AAYTwIapvwUDQhhJOA05ufowtodISQBiAfoK4u_Pz7n1lW1cFWzwW4rcaudbFwl9riqWz8Pa4WNtFXZ-a_5bYZ1c-Ce9KJvtV7peYtfK7fFy2yKRVOOsdLmQKnKWIe9gRz3dWW8wLhGGjvGne09xaGL_e6lDLRSuJb-slLv9eb9Ep0psbfy6vcdoue7-Wr2ECyW94-z6SIoIExpEMVFmBKpCpoqwuKQgyiFpEmc8ohTwTmRQFkpw3UMEUsISxgjZA0ggXkhoUM0Os5tjX7ppHX5Tnem8ZZ5GKUsjVKv8VR8pIp69wcAyfs48mMceR9H_j-OHCj9AZblhIU</recordid><startdate>20211108</startdate><enddate>20211108</enddate><creator>Tolley, K</creator><creator>Mettam, S</creator><creator>Noble-Longster, J</creator><creator>Hibbs, R</creator><creator>Stainer, L</creator><creator>Cawson, M</creator><creator>Snell, T</creator><creator>Manuel, A</creator><general>BMJ Publishing Group Ltd and British Thoracic Society</general><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20211108</creationdate><title>S7 Estimating the potential impact of residual EDS on the QoL of patients with OSA and, for the first time, their partners, using a time trade-off methodology</title><author>Tolley, K ; Mettam, S ; Noble-Longster, J ; Hibbs, R ; Stainer, L ; Cawson, M ; Snell, T ; Manuel, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1293-57b290efb39f047261adae38796563a660e134de2c715480484400c11e1429003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Patients</topic><topic>Sleep apnea</topic><topic>Stay awake! It’s an update on sleep</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tolley, K</creatorcontrib><creatorcontrib>Mettam, S</creatorcontrib><creatorcontrib>Noble-Longster, J</creatorcontrib><creatorcontrib>Hibbs, R</creatorcontrib><creatorcontrib>Stainer, L</creatorcontrib><creatorcontrib>Cawson, M</creatorcontrib><creatorcontrib>Snell, T</creatorcontrib><creatorcontrib>Manuel, A</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Thorax</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tolley, K</au><au>Mettam, S</au><au>Noble-Longster, J</au><au>Hibbs, R</au><au>Stainer, L</au><au>Cawson, M</au><au>Snell, T</au><au>Manuel, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>S7 Estimating the potential impact of residual EDS on the QoL of patients with OSA and, for the first time, their partners, using a time trade-off methodology</atitle><jtitle>Thorax</jtitle><stitle>Thorax</stitle><date>2021-11-08</date><risdate>2021</risdate><volume>76</volume><issue>Suppl 2</issue><spage>A8</spage><epage>A9</epage><pages>A8-A9</pages><issn>0040-6376</issn><eissn>1468-3296</eissn><abstract>Introduction and ObjectivesExcessive daytime sleepiness (EDS) is a common symptom of obstructive sleep apnoea (OSA), persisting in 9% to 22% of patients despite primary airway therapy (residual EDS). EDS can impair work productivity and driving ability, and negatively impact quality of life (QoL) of patients and their partners.This study aimed to elicit QoL values (utilities) from a societal perspective for patients with OSA with residual EDS of varying severity and, for the first time, for the partners of these patients, using a novel time trade-off (TTO) approach.MethodsUtility values for health states of varying severities of residual EDS in OSA were elicited using the TTO method in a study conducted with a United Kingdom general public sample (N=110). Four EDS severity health state descriptions were developed from both patient and partner perspectives (no EDS, mild EDS, moderate EDS, severe EDS). During face-to-face interviews, participants were asked to ‘trade off’ time for each EDS health state for a shorter period in full health (0–10 years), first for the patient health states and then for the partner health states. TTO responses were converted to utility values (scale of 0–1, where 0 represents QoL equivalent to death and 1 represents the highest QoL).ResultsMean utility scores declined with increasing EDS severity (table 1). In the context of the TTO exercise, participants were prepared to trade a mean of 4.5 life-years (out of a maximum of 10) to avoid the QoL consequences of severe EDS compared with best imaginable health and 3.3 life-years to avoid the QoL impact associated with being the partner of a patient with severe EDS.Abstract S7 Table 1Utility values for patient and partner health states (N=104)a Utility Valuesb Mean SD Patient health states 1. No EDS 0.93 0.11 2. Mild EDS 0.79 0.17 3. Moderate EDS 0.61 0.22 4. Severe EDS 0.55 0.24 Partner health states 5. No EDS 0.95 0.08 6. Mild EDS 0.88 0.13 7. Moderate EDS 0.75 0.23 8. Severe EDS 0.67 0.26 EDS, excessive daytime sleepiness; SD, standard deviation. aAll values rounded to 2 decimal places. bBased on a scale of 0–1, where 0 represents QoL equivalent to death and 1 represents the highest QoL.ConclusionsThese results demonstrate the high potential impact of residual EDS on the QoL of patients with OSA and their partners. Estimated utility values for patients and partners declined with increased EDS severity. This is the first time that the impact of residual EDS in OSA on QoL and utility has been measured from the partner perspective, highlighting the range of potential benefits that could result from the use of novel treatment options (alongside primary airway therapy) for residual EDS.Please refer to page A188 for declarations of interest related to this abstract.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and British Thoracic Society</pub><doi>10.1136/thorax-2021-BTSabstracts.13</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0040-6376 |
ispartof | Thorax, 2021-11, Vol.76 (Suppl 2), p.A8-A9 |
issn | 0040-6376 1468-3296 |
language | eng |
recordid | cdi_proquest_journals_2594959048 |
source | Alma/SFX Local Collection |
subjects | Patients Sleep apnea Stay awake! It’s an update on sleep |
title | S7 Estimating the potential impact of residual EDS on the QoL of patients with OSA and, for the first time, their partners, using a time trade-off methodology |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T11%3A56%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_j&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=S7%E2%80%85Estimating%20the%20potential%20impact%20of%20residual%20EDS%20on%20the%20QoL%20of%20patients%20with%20OSA%20and,%20for%20the%20first%20time,%20their%20partners,%20using%20a%20time%20trade-off%20methodology&rft.jtitle=Thorax&rft.au=Tolley,%20K&rft.date=2021-11-08&rft.volume=76&rft.issue=Suppl%202&rft.spage=A8&rft.epage=A9&rft.pages=A8-A9&rft.issn=0040-6376&rft.eissn=1468-3296&rft_id=info:doi/10.1136/thorax-2021-BTSabstracts.13&rft_dat=%3Cproquest_bmj_j%3E2594959048%3C/proquest_bmj_j%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2594959048&rft_id=info:pmid/&rfr_iscdi=true |